Form 4: Tenaya Therapeutics Director Receives Stock Option Grant

Director Karah Herdman Parschauer was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Summary

• Director Karah Herdman Parschauer received a grant of 120,000 stock options on May 28, 2026.
• The options have an exercise price of $0.7989 per share.
• The grant is subject to a vesting schedule with full vesting occurring on May 28, 2027, or the day before the next annual stockholders meeting, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of Tenaya Therapeutics common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The one-year vesting period is a common retention mechanism for board members in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 28, 2027.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Stock Options, Director Compensation, Equity Incentive Plan